PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
USA - NASDAQ:PCRX - US6951271005 - Common Stock
22.26 USD
-0.09 (-0.4%)
22.26 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to PCRX. PCRX was compared to 195 industry peers in the Pharmaceuticals industry. PCRX has only an average score on both its financial health and profitability. PCRX is valued quite cheap, but it does not seem to be growing. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
PCRX had positive earnings in 4 of the past 5 years.
PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PCRX has a Return On Assets of -8.29%. This is in the better half of the industry: PCRX outperforms 68.72% of its industry peers.
With a decent Return On Equity value of -16.82%, PCRX is doing good in the industry, outperforming 70.26% of the companies in the same industry.
PCRX's Return On Invested Capital of 3.88% is amongst the best of the industry. PCRX outperforms 81.03% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 15.30%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROIC | 3.88% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
1.3 Margins
With an excellent Operating Margin value of 9.90%, PCRX belongs to the best of the industry, outperforming 82.56% of the companies in the same industry.
In the last couple of years the Operating Margin of PCRX has grown nicely.
With an excellent Gross Margin value of 78.19%, PCRX belongs to the best of the industry, outperforming 83.59% of the companies in the same industry.
PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% |
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PCRX has less shares outstanding
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
PCRX has an Altman-Z score of 1.53. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PCRX (1.53) is better than 61.03% of its industry peers.
PCRX has a debt to FCF ratio of 4.96. This is a neutral value as PCRX would need 4.96 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.96, PCRX belongs to the best of the industry, outperforming 83.59% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
PCRX has a Debt to Equity ratio (0.50) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Altman-Z | 1.53 |
ROIC/WACC0.53
WACC7.3%
2.3 Liquidity
PCRX has a Current Ratio of 2.38. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Current ratio (2.38) which is comparable to the rest of the industry.
A Quick Ratio of 1.91 indicates that PCRX should not have too much problems paying its short term obligations.
PCRX has a Quick ratio (1.91) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
The earnings per share for PCRX have decreased by -1.92% in the last year.
PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
The Revenue for PCRX has decreased by -17.68% in the past year. This is quite bad
Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
3.2 Future
PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.92% yearly.
Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.56% on average per year.
EPS Next Y-9.5%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 7.27, the valuation of PCRX can be described as very cheap.
PCRX's Price/Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.33% of the companies in the same industry.
PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.02.
PCRX is valuated cheaply with a Price/Forward Earnings ratio of 6.69.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (22.57), we can say PCRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.27 | ||
| Fwd PE | 6.69 |
4.2 Price Multiples
PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 94.87% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaply inside the industry as 91.79% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.54 | ||
| EV/EBITDA | 6.21 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.52
EPS Next 2Y1.81%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.26
-0.09 (-0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.55%
Inst Owner Change-0.45%
Ins Owners0.81%
Ins Owner Change0.59%
Market Cap1.00B
Analysts76.92
Price Target38.15 (71.38%)
Short Float %15.15%
Short Ratio9.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.06%
Min EPS beat(2)1.99%
Max EPS beat(2)2.13%
EPS beat(4)4
Avg EPS beat(4)5.22%
Min EPS beat(4)1.99%
Max EPS beat(4)9.93%
EPS beat(8)5
Avg EPS beat(8)3.99%
EPS beat(12)6
Avg EPS beat(12)-0.53%
EPS beat(16)8
Avg EPS beat(16)-3.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.46%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.49%
Revenue beat(12)1
Avg Revenue beat(12)-2.62%
Revenue beat(16)1
Avg Revenue beat(16)-2.55%
PT rev (1m)0%
PT rev (3m)-3.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.39%
EPS NY rev (1m)0.49%
EPS NY rev (3m)-1.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.27 | ||
| Fwd PE | 6.69 | ||
| P/S | 1.42 | ||
| P/FCF | 8.54 | ||
| P/OCF | 7.43 | ||
| P/B | 1.32 | ||
| P/tB | 3.18 | ||
| EV/EBITDA | 6.21 |
EPS(TTM)3.06
EY13.75%
EPS(NY)3.33
Fwd EY14.95%
FCF(TTM)2.61
FCFY11.71%
OCF(TTM)2.99
OCFY13.45%
SpS15.71
BVpS16.87
TBVpS7.01
PEG (NY)N/A
PEG (5Y)0.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROCE | 5.71% | ||
| ROIC | 3.88% | ||
| ROICexc | 6.11% | ||
| ROICexgc | 14.17% | ||
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% | ||
| FCFM | 16.59% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 19.4% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 4.34 | ||
| Cash Conversion | 84.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 1.53 |
F-Score5
WACC7.3%
ROIC/WACC0.53
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
EPS Next Y-9.5%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
EBIT growth 1Y-39.89%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year0.19%
EBIT Next 3Y7.79%
EBIT Next 5Y6.85%
FCF growth 1Y-7.53%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-8.67%
OCF growth 3Y14.64%
OCF growth 5Y21.85%